WHAT IS CLAIMED IS:

- 1. An isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 70 % identical to SEQ ID NO: 1, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.
- 2. The isolated polynucleotide of claim 1, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 3.
- 3.` The isolated polynucleotide of claim 1, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 4.
- 4. The isolated polynucleotide of claim 1, wherein said polypeptide is as set forth in SEQ ID NO: 1.
- 5. The isolated polynucleotide of claim 1, wherein said polypeptide is as set forth in SEQ ID NO: 2.
 - 6. An isolated polynucleotide as set forth in SEQ ID NO: 4.
 - 7. An isolated polynucleotide as set forth in SEQ ID NO: 3.
 - 8. An isolated polypeptide as set forth in SEQ ID NO: 1.
 - 9. An isolated polypeptide as set forth in SEQ ID NO: 2.
- 10. A nucleic acid construct comprising the isolated polynucleotide of claim 1.
- 11. The nucleic acid construct of claim 10, further comprising a promoter for regulating transcription of the isolated polynucleotide in sense or antisense orientation.

- 12. The nucleic acid construct of claim 10, further comprising a positive and a negative selection markers for selecting for homologous recombination events.
 - 13. A host cell comprising the nucleic acid construct of claim 10.
- 14. An isolated polypeptide comprising an amino acid sequence at least 70 % identical to SEQ ID NO: 1, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters or an active portion thereof.
- 15. An antibody or an antibody fragment being capable of specifically binding a polypeptide having an amino acid sequence at least 70 % identical to SEQ ID NO: 1, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.
- 16. An oligonucleotide specifically hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 70 % identical to SEQ ID NO: 1, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.
- 17. A pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 70 % identical to SEQ ID NO: 1, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters and a pharmaceutically acceptable carrier or diluent.
- 18. A method of treating Met-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 70 % identical to SEQ ID NO: 1 as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters, thereby treating the Met-related disease in a subject.

- 19. The method of claim 18, wherein said upregulating expression of said polypeptide is effected by:
 - (i) administering said polypeptide to the subject; and/or
 - (ii) administering an expressible polynucleotide encoding said polypeptide to the subject.
- 20. An isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 75 % identical to SEQ ID NO: 5, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.
- 21. The isolated polynucleotide of claim 20, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 8.
- 22. The isolated polynucleotide of claim 20, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 7.
- 23. The isolated polynucleotide of claim 20, wherein said polypeptide is as set forth in SEQ ID NO: 5.
- 24. The isolated polynucleotide of claim 20, wherein said polypeptide is as set forth in SEQ ID NO: 6.
 - 25. An isolated polynucleotide as set forth in SEQ ID NO: 8.
 - 26. An isolated polynucleotide as set forth in SEQ ID NO: 7.
 - 27. An isolated polypeptide as set forth in SEQ ID NO: 5.
 - 28. An isolated polypeptide as set forth in SEQ ID NO: 6.
- 29. A nucleic acid construct comprising the isolated polynucleotide of claim 20.

- 30. The nucleic acid construct of claim 29, further comprising a promoter for regulating transcription of the isolated polynucleotide in sense or antisense orientation.
- 31. The nucleic acid construct of claim 29, further comprising a positive and a negative selection markers for selecting for homologous recombination events.
 - 32. A host cell comprising the nucleic acid construct of claim 29.
- 33. An isolated polypeptide comprising an amino acid sequence at least 75 % identical to SEQ ID NO: 5, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters or an active portion thereof.
- 34. An antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 75 % identical to SEQ ID NO: 5, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.
- 35. An oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 75 % identical to SEQ ID NO: 5, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.
- 36. A pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 75 % identical to SEQ ID NO: 5, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters and a pharmaceutically acceptable carrier or diluent.
- 37. A method of treating an IL-6-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 75 % identical to SEQ ID NO: 5 as determined using the

LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters, thereby treating the IL-6-related disease in the subject.

- 38. The Method of claim 37, wherein said upregulating expression of said polypeptide is effected by:
 - (i) administering said polypeptide to the subject; and/or
 - (ii) administering an expressible polynucleotide encoding said polypeptide to the subject.
- 39. An isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 85 % identical to SEQ ID NO: 9, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.
- 40. The isolated polynucleotide of claim 39, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 11.
- 41. The isolated polynucleotide of claim 39, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 12.
- 42. The isolated polynucleotide of claim 39, wherein said polypeptide is as set forth in SEQ ID NO: 9.
- 43. The isolated polynucleotide of claim 39, wherein said polypeptide is as set forth in SEQ ID NO: 10.
 - 44. An isolated polynucleotide as set forth in SEQ ID NO: 11.
 - 45. An isolated polynucleotide as set forth in SEQ ID NO: 12.
 - 46. An isolated polypeptide as set forth in SEQ ID NO: 10.
 - 47. An isolated polypeptide as set forth in SEQ ID NO: 9.

- 48. A nucleic acid construct comprising the isolated polynucleotide of claim 39.
- 49. The nucleic acid construct of claim 48, further comprising a promoter for regulating transcription of the isolated polynucleotide in sense or antisense orientation.
- 50. The nucleic acid construct of claim 48, further comprising a positive and a negative selection markers for selecting for homologous recombination events.
 - 51. A host cell comprising the nucleic acid construct of claim 48.
- 52. An isolated polypeptide comprising an amino acid sequence at least 85 % identical to SEQ ID NO: 9, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters or an active portion thereof.
- 53. An antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 85 % identical to SEQ ID NO: 9, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.
- 54. An oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 85 % identical to SEQ ID NO: 9, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.
- 55. A pharmaceutical composition comprising a therapeutically effective amount of a IL-7 polypeptide having an amino acid sequence at least 85 % identical to SEQ ID NO: 9, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters and a pharmaceutically acceptable carrier or diluent.

- 56. A method of treating IL-7-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 85 % identical to SEQ ID NO: 9 as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.
- 57. The method of claim 56, wherein said upregulating expression of said polypeptide is effected by:
 - (i) administering said polypeptide to the subject; and/or
 - (ii) administering an expressible polynucleotide encoding said polypeptide to the subject.
- 58. An isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 85 % identical to SEQ ID NO: 13, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.
- 59. The isolated polynucleotide of claim 58, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 15.
- 60. The isolated polynucleotide of claim 58, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 16.
- 61. The isolated polynucleotide of claim 58, wherein said polypeptide is as set forth in SEQ ID NO: 13.
- 62. The isolated polynucleotide of claim 58, wherein said polypeptide is as set forth in SEQ ID NO: 14.
 - 63. An isolated polynucleotide as set forth in SEQ ID NO: 15.
 - 64. An isolated polynucleotide as set forth in SEQ ID NO: 16.

- 65. An isolated polypeptide as set forth in SEQ ID NO: 13.
- 66. An isolated polypeptide as set forth in SEQ ID NO: 14.
- 67. A nucleic acid construct comprising the isolated polynucleotide of claim 58.
- 68. The nucleic acid construct of claim 67, further comprising a promoter for regulating transcription of the isolated polynucleotide in sense or antisense orientation.
- 69. The nucleic acid construct of claim 67, further comprising a positive and a negative selection markers for selecting for homologous recombination events.
 - 70. A host cell comprising the nucleic acid construct of claim 67.
- 71. An isolated polypeptide comprising an amino acid sequence at least 85 % identical to SEQ ID NO: 13, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters or an active portion thereof.
- 72. An antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 85 % identical to SEQ ID NO: 13, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.
- 73. An oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 85 % identical to SEQ ID NO: 13, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.
- 74. A pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 85 % identical to

SEQ ID NO: 13, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters and a pharmaceutically acceptable carrier or diluent.

- 75. A method of treating IL-7-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 85 % identical to SEQ ID NO: 13 as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.
- 76. The method of claim 75, wherein said upregulating expression of said polypeptide is effected by:
 - (i) administering said polypeptide to the subject; and/or
 - (ii) administering an expressible polynucleotide encoding said polypeptide to the subject.
- 77. An isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 60 % identical to SEQ ID NO: 17, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.
- 78. The isolated polynucleotide of claim 77, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 19.
- 79. The isolated polynucleotide of claim 77, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 20.
- 80. The isolated polynucleotide of claim 77, wherein said polypeptide is as set forth in SEQ ID NO: 17.
- 81. The isolated polynucleotide of claim 77, wherein said polypeptide is as set forth in SEQ ID NO: 18.

- 82. An isolated polynucleotide as set forth in SEQ ID NO: 19.
- 83. An isolated polynucleotide as set forth in SEQ ID NO: 20.
- 84. An isolated polypeptide as set forth in SEQ ID NO: 17.
- 85. An isolated polypeptide as set forth in SEQ ID NO: 18.
- 86. A nucleic acid construct comprising the isolated polynucleotide of claim 77.
- 87. The nucleic acid construct of claim 86, further comprising a promoter for regulating transcription of the isolated polynucleotide in sense or antisense orientation.
- 88. The nucleic acid construct of claim 86, further comprising a positive and a negative selection markers for selecting for homologous recombination events.
 - 89. A host cell comprising the nucleic acid construct of claim 86.
- 90. An isolated polypeptide comprising an amino acid sequence at least 60 % identical to SEQ ID NO: 17, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters or an active portion thereof.
- 91. An antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 60 % identical to SEQ ID NO: 17, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.
- 92. An oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 60 % identical to SEQ ID NO: 17, as

determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

- 93. A pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 60 % identical to SEQ ID NO: 17, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters and a pharmaceutically acceptable carrier or diluent.
- 94. A method of treating TNFR9-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 60 % identical to SEQ ID NO: 17 as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.
- 95. The method of claim 94, wherein said upregulating expression of said polypeptide is effected by:
 - (i) administering said polypeptide to the subject; and/or
 - (ii) administering an expressible polynucleotide encoding said polypeptide to the subject.
- 96. An isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 25, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.
- 97. The isolated polynucleotide of claim 96, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 27.
- 98. The isolated polynucleotide of claim 96, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 28.

- 99. The isolated polynucleotide of claim 96, wherein said polypeptide is as set forth in SEQ ID NO: 25.
- 100. The isolated polynucleotide of claim 96, wherein said polypeptide is as set forth in SEQ ID NO: 26.
 - 101. An isolated polynucleotide as set forth in SEQ ID NO: 27.
 - 102. An isolated polynucleotide as set forth in SEQ ID NO: 28.
 - 103. An isolated polypeptide as set forth in SEQ ID NO: 25.
 - 104. An isolated polypeptide as set forth in SEQ ID NO: 26.
- 105. A nucleic acid construct comprising the isolated polynucleotide of claim 96.
- 106. The nucleic acid construct of claim 105, further comprising a promoter for regulating transcription of the isolated polynucleotide in sense or antisense orientation.
- 107. The nucleic acid construct of claim 105, further comprising a positive and a negative selection markers for selecting for homologous recombination events.
 - 108. A host cell comprising the nucleic acid construct of claim 105.
- 109. An isolated polypeptide comprising an amino acid sequence at least 50 % identical to SEQ ID NO: 25, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters or an active portion thereof.
- 110. An antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 25,

as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

- 111. An oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 50 % identical to SEQ ID NO: 25, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.
- 112. A pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 25, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters and a pharmaceutically acceptable carrier or diluent.
- 113. A method of treating IL-4R-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 25 as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.
- 114. The method of claim 113, wherein said upregulating expression of said polypeptide is effected by:
 - (i) administering said polypeptide to the subject; and/or
 - (ii) administering an expressible polynucleotide encoding said polypeptide to the subject.
- 115. An isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 21, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.
- 116. The isolated polynucleotide of claim 115, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 24.

- 117. The isolated polynucleotide of claim 115, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 23.
- 118. The isolated polynucleotide of claim 115, wherein said polypeptide is as set forth in SEQ ID NO: 21.
- 119. The isolated polynucleotide of claim 115, wherein said polypeptide is as set forth in SEQ ID NO: 22.
 - 120. An isolated polynucleotide as set forth in SEQ ID NO: 23.
 - 121. An isolated polynucleotide as set forth in SEQ ID NO: 24.
 - 122. An isolated polypeptide as set forth in SEQ ID NO: 21.
 - 123. An isolated polypeptide as set forth in SEQ ID NO: 22.
- 124. A nucleic acid construct comprising the isolated polynucleotide of claim 115.
- 125. The nucleic acid construct of claim 124, further comprising a promoter for regulating transcription of the isolated polynucleotide in sense or antisense orientation.
- 126. The nucleic acid construct of claim 124, further comprising a positive and a negative selection markers for selecting for homologous recombination events.
 - 127. A host cell comprising the nucleic acid construct of claim 124.
- 128. An isolated polypeptide comprising an amino acid sequence at least 50 % identical to SEQ ID NO: 21, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters or an active portion thereof.

- 129. An antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 21, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.
- 130. An oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 50 % identical to SEQ ID NO: 21, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.
- 131. A pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 21, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters and a pharmaceutically acceptable carrier or diluent.
- 132. A method of treating IL-4R-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 21 as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.
- 133. The method of claim 132, wherein said upregulating expression of said polypeptide is effected by:
 - (i) administering said polypeptide to the subject; and/or
 - (ii) administering an expressible polynucleotide encoding said polypeptide to the subject.
- 134. An isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 29, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

- 135. The isolated polynucleotide of claim 134, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 31.
- 136. The isolated polynucleotide of claim 134, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 32.
- 137. The isolated polynucleotide of claim 134, wherein said polypeptide is as set forth in SEQ ID NO: 29.
- 138. The isolated polynucleotide of claim 134, wherein said polypeptide is as set forth in SEQ ID NO: 30.
 - 139. An isolated polynucleotide as set forth in SEQ ID NO: 31.
 - 140. An isolated polynucleotide as set forth in SEQ ID NO: 32.
 - 141. An isolated polypeptide as set forth in SEQ ID NO: 29.
 - 142. An isolated polypeptide as set forth in SEQ ID NO: 30.
- 143. A nucleic acid construct comprising the isolated polynucleotide of claim 134.
- 144. The nucleic acid construct of claim 143, further comprising a promoter for regulating transcription of the isolated polynucleotide in sense or antisense orientation.
- 145. The nucleic acid construct of claim 143, further comprising a positive and a negative selection markers for selecting for homologous recombination events.
 - 146. A host cell comprising the nucleic acid construct of claim 143.

- 147. An isolated polypeptide comprising an amino acid sequence at least 50 % identical to SEQ ID NO: 29, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters or an active portion thereof.
- 148. An antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 29, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.
- 149. An oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 50 % identical to SEQ ID NO: 29, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.
- 150. A pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 29, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters and a pharmaceutically acceptable carrier or diluent.
- 151. A method of treating TGR2-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 50 % identical to SEQ ID NO: 29 as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.
- 152. The method of claim 151, wherein said upregulating expression of said polypeptide is effected by:
 - (i) administering said polypeptide to the subject; and/or
 - (ii) administering an expressible polynucleotide encoding said polypeptide to the subject.

- 153. An isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 80 % identical to SEQ ID NO: 33, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.
- 154. The isolated polynucleotide of claim 153, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 35.
- 155. The isolated polynucleotide of claim 153, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 36.
- 156. The isolated polynucleotide of claim 153, wherein said polypeptide is as set forth in SEQ ID NO: 33.
- 157. The isolated polynucleotide of claim 153, wherein said polypeptide is as set forth in SEQ ID NO: 34.
 - 158. An isolated polynucleotide as set forth in SEQ ID NO: 35.
 - 159. An isolated polynucleotide as set forth in SEQ ID NO: 36.
 - 160. An isolated polypeptide as set forth in SEQ ID NO: 33.
 - 161. An isolated polypeptide as set forth in SEQ ID NO: 34.
- 162. A nucleic acid construct comprising the isolated polynucleotide of claim 153.
- 163. The nucleic acid construct of claim 162, further comprising a promoter for regulating transcription of the isolated polynucleotide in sense or antisense orientation.

- 164. The nucleic acid construct of claim 162, further comprising a positive and a negative selection markers for selecting for homologous recombination events.
 - 165. A host cell comprising the nucleic acid construct of claim 162.
- 166. An isolated polypeptide comprising an amino acid sequence at least 80 % identical to SEQ ID NO: 33, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters or an active portion thereof.
- 167. An antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 80 % identical to SEQ ID NO: 33, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.
- 168. An oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 80 % identical to SEQ ID NO: 33, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.
- 169. A pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 80 % identical to SEQ ID NO: 33, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters and a pharmaceutically acceptable carrier or diluent.
- 170. A method of treating ITAV-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 80 % identical to SEQ ID NO: 33 as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

- 171. The method of claim 170, wherein said upregulating expression of said polypeptide is effected by:
 - (i) administering said polypeptide to the subject; and/or
 - (ii) administering an expressible polynucleotide encoding said polypeptide to the subject.
- 172. An isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 70 % identical to SEQ ID NO: 37, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.
- 173. The isolated polynucleotide of claim 172, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 39.
- 174. The isolated polynucleotide of claim 172, wherein said polypeptide is as set forth in SEQ ID NO: 37.
- 175. The isolated polynucleotide of claim 172, wherein said polypeptide is as set forth in SEQ ID NO: 38.
 - 176. An isolated polynucleotide as set forth in SEQ ID NO: 39.
 - 177. An isolated polypeptide as set forth in SEQ ID NO: 37.
 - 178. An isolated polypeptide as set forth in SEQ ID NO: 38.
- 179. A nucleic acid construct comprising the isolated polynucleotide of claim 172.
- 180. The nucleic acid construct of claim 179, further comprising a promoter for regulating transcription of the isolated polynucleotide in sense or antisense orientation.

- 181. The nucleic acid construct of claim 179, further comprising a positive and a negative selection markers for selecting for homologous recombination events.
 - 182. A host cell comprising the nucleic acid construct of claim 179.
- 183. An isolated polypeptide comprising an amino acid sequence at least 70 % identical to SEQ ID NO: 37, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters or an active portion thereof.
- 184. An antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 70 % identical to SEQ ID NO: 37, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.
- 185. An oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 70 % identical to SEQ ID NO: 37, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.
- 186. A pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 70 % identical to SEQ ID NO: 37, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters and a pharmaceutically acceptable carrier or diluent.
- 187. A method of treating IL10-R-B-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 70 % identical to SEQ ID NO: 37 as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

- 188. The method of claim 187, wherein said upregulating expression of said polypeptide is effected by:
 - (i) administering said polypeptide to the subject; and/or
 - (ii) administering an expressible polynucleotide encoding said polypeptide to the subject.
- 189. An isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence at least 80 % identical to SEQ ID NO: 41, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.
- 190. The isolated polynucleotide of claim 189, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 43.
- 191. The isolated polynucleotide of claim 189, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 40.
- 192. The isolated polynucleotide of claim 189, wherein said polypeptide is as set forth in SEQ ID NO: 41.
- 193. The isolated polynucleotide of claim 189, wherein said polypeptide is as set forth in SEQ ID NO: 42.
 - 194. An isolated polynucleotide as set forth in SEQ ID NO: 43.
 - 195. An isolated polynucleotide as set forth in SEQ ID NO: 40.
 - 196. An isolated polypeptide as set forth in SEQ ID NO: 41.
 - 197. An isolated polypeptide as set forth in SEQ ID NO: 42.
- 198. A nucleic acid construct comprising the isolated polynucleotide of claim 189.

- 199. The nucleic acid construct of claim 189, further comprising a promoter for regulating transcription of the isolated polynucleotide in sense or antisense orientation.
- 200. The nucleic acid construct of claim 189, further comprising a positive and a negative selection markers for selecting for homologous recombination events.
 - 201. A host cell comprising the nucleic acid construct of claim 198.
- 202. An isolated polypeptide comprising an amino acid sequence at least 80 % identical to SEQ ID NO: 41, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters or an active portion thereof.
- 203. An antibody or an antibody fragment being capable of binding a polypeptide having an amino acid sequence at least 80 % identical to SEQ ID NO: 41, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.
- 204. An oligonucleotide hybridizable with a nucleic acid sequence encoding a polypeptide having an amino acid at least 80 % identical to SEQ ID NO: 41, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.
- 205. A pharmaceutical composition comprising a therapeutically effective amount of a polypeptide having an amino acid sequence at least 80 % identical to SEQ ID NO: 41, as determined using the LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters and a pharmaceutically acceptable carrier or diluent.
- 206. A method of treating INR1-related disease in a subject, the method comprising upregulating in the subject expression of a polypeptide having an amino acid sequence at least 80 % identical to SEQ ID NO: 41 as determined using the

LALIGN software of EMBnet switzerland (http://www.ch.embnet.org/index.html) using default parameters.

- 207. The method of claim 206, wherein said upregulating expression of said polypeptide is effected by:
 - (i) administering said polypeptide to the subject; and/or
 - (ii) administering an expressible polynucleotide encoding said polypeptide to the subject.